Cost-effective to the biological form of DMARDs (bDMARDs)

Assessment of the inexpensive biological form of DMARDs (bDMARDs)
Recent updates to the DMARD guidelines when patients with rheumatoid arthritis achieve remission or low disease activity.

Can a remission be achieved at all?

A sensitive topic about which our rheumatics were allowed to gain their own experience

The payer’s perspective for Germany and conducted deterministic and probabilistic sensitivity analyses.